IQVIA (NYSE:IQV) Shares Unloaded Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of IQVIA Holdings Inc. NYSE: IQV. In a filing disclosed on March 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
• Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
• Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.

IQVIA Price Performance

Shares of IQVIA stock traded down $1.12 during trading on Monday, reaching $176.28. The company's stock had a trading volume of 2,234,715 shares, compared to its average volume of 1,303,021. IQVIA Holdings Inc. has a one year low of $169.54 and a one year high of $253.84. The stock has a 50-day moving average price of $193.15 and a two-hundred day moving average price of $206.05. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $31.08 billion, a P/E ratio of 23.50, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IQV. Stephens started coverage on IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 price target on the stock. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. Royal Bank of Canada restated an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Morgan Stanley lifted their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Finally, Citigroup cut their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $249.05.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after acquiring an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after purchasing an additional 712,958 shares during the last quarter. Geode Capital Management LLC grew its position in IQVIA by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after purchasing an additional 77,981 shares in the last quarter. FMR LLC lifted its position in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after buying an additional 804,963 shares in the last quarter. Finally, Invesco Ltd. lifted its position in IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after buying an additional 902,226 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.